Explore News By Topic
05/17/2017
Study finds genetic difference in prostate cancer in African-Americans
Dana-Farber Cancer Institute News Release May 17,2017 The genomic discovery may partly explain why prostate cancer is more aggressive in black men Scientists say more blacks and other under-represented groups should be included in genomic studies to enable precision medicine BOSTON –– A new genomic study has identified prostate cancer... Read More
05/11/2017
Scientists Identify Biomarkers to Guide Hormone Therapy for Prostate Cancer
University of California San Francisco News Release May 11, 2017 A test commonly used in breast cancer has been found to also identify which patients with aggressive prostate cancer will benefit from hormonal therapy, according to a study led by scientists at UC San Francisco and the University of Michigan.... Read More
05/08/2017
Advanced Prostate Cancer Treatment Failure Due to Cell Reprogramming
New York, NY (May 4, 2017)—Columbia University Medical Center (CUMC) researchers have discovered a molecular mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy. The findings, based on a study in mice, could help to determine which patients should avoid anti-androgen therapy... Read More
05/02/2017
Why has checkpoint immunotherapy been ineffective in treating prostate cancer?
Checkpoint immunotherapy, the relatively new type of cancer treatment making headlines for being able to seemingly cure some patients with melanoma and other cancers, has been notoriously ineffective in prostate cancer. At the 2017 American Association for Cancer Research (AACR) Annual Meeting, Dr. Padmanee Sharma presented the discovery of at... Read More
04/20/2017
Tumor-targeting CAR T cell immunotherapy finally works in solid tumors; soon to be in trials for prostate cancer
Immune cells that are genetically engineered with designer molecules to recognize and kill cancer cells may sound like an episode of science fiction, and for solid tumors, they used to be – until now. At the 2017 American Association for Cancer Research (AACR) Annual Meeting, City of Hope National Cancer... Read More
04/14/2017
PCF Position: USPSTF Improves Draft Recommendation for Prostate Cancer Screening
The Prostate Cancer Foundation (PCF) commends and applauds the Task Force on the proposed revised guidelines and its emphasis on shared decision-making between a patient and clinician. After draft evidence reviews on screening for prostate cancer the Task Force determined that “potential benefits and harms of prostate-specific antigen (PSA)–based screening... Read More
03/29/2017
Study provides path for new immunotherapy approaches to prostate cancer
MD Anderson News Release 03/27/2017 Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine. Based on... Read More
03/29/2017
2017 AACR-Prostate Cancer Foundation Scholar-in-Training Award Recipients
The Prostate Cancer Foundation Scholar-in-Training Awards recognize promising young cancer researchers presenting outstanding proffered papers relating to advanced prostate cancer at the American Association for Cancer Research (AACR) Annual Meeting. The Prostate Cancer Foundation is one of 18 organizations sponsoring this highly competitive awards program in conjunction with the AACR.... Read More
03/23/2017
A new approach to target an ‘undruggable’ prostate cancer driver
ANN ARBOR, Michigan — New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers. When the genes TMPRSS2 and ERG relocate on a chromosome and fuse together, it’s an on-switch for prostate cancer development. But ERG has proven to be a... Read More
03/13/2017
PCF-Funded Research Reveals Gene Mutation as Driver of Prostate Cancer Subtype
A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches. A mutation of the gene Speckle Type BTB/POZ Protein, or... Read More